IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i8p4631-d791894.html
   My bibliography  Save this article

Incidence and Predictors of Loss to Follow Up among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study

Author

Listed:
  • Roger T. Buju

    (Department of Public Health, Faculté de Medicine, University of Bunia, Bunia P.O. Box 292, Democratic Republic of the Congo)

  • Pierre Z. Akilimali

    (Department of Biostatistics and Epidemiology, Kinshasa School of Public Health, University of Kinshasa, Kinshasa P.O. Box 11850, Democratic Republic of the Congo)

  • Erick N. Kamangu

    (Département des Sciences de Base, School of Medicine, University of Kinshasa, Kinshasa P.O. Box 11850, Democratic Republic of the Congo)

  • Gauthier K. Mesia

    (Unité de Pharmacologie Clinique, School of Medicine, University of Kinshasa, Kinshasa P.O. Box 11850, Democratic Republic of the Congo)

  • Jean Marie N. Kayembe

    (Department Internal Medicine, School of Medicine, University of Kinshasa, Kinshasa P.O. Box 11850, Democratic Republic of the Congo)

  • Hippolyte N. Situakibanza

    (Department Internal Medicine, School of Medicine, University of Kinshasa, Kinshasa P.O. Box 11850, Democratic Republic of the Congo
    Department of Tropical Medicine, Infectious and Parasitic Diseases, School of Medicine, University of Kinshasa, Kinshasa P.O. Box 11850, Democratic Republic of the Congo)

Abstract

This study aimed to examine the incidence and predictors of loss to follow up (LTFU) in the context of ongoing atrocities caused by armed conflict, where HIV treatment programs and HIV-infected patients may face unique challenges in terms of ART adherence and retention in care. We conducted an observational prospective cohort study of 468 patients living with HIV (PLWHIV) under dolutegravir (DTG) in all health facilities in Bunia between July 2019 and July 2021. Kaplan–Meier plots were used to determine the probability of LTFU as a function of time as inclusive of the cohort. The main outcome variable was LTFU, defined as not taking an ART refill for a period of 3 months or longer from the last attendance for refill, and not yet classified as ‘dead’ or ‘transferred-out.’ The log-rank test was used to compare survival curves based on predictors. Cox proportional hazard modeling was used to measure predictors of LTFU from the baseline until 31 July 2021 (the endpoint). A total of 3435.22 person-months (p-m) were involved in follow up, with an overall incidence rate of 33.48 LTFU per 1000 p-m. Patients who had less experience with ART at enrolment and the ethnically Sudanese, had a higher hazard of being LTFU compared to their reference groups. This study reports a high LTFU rate in this conflict setting. An ART program in such a setting should pay more attention to naive patients and other particularly vulnerable patients such as Sudanese during the pre-ART phase. The study implies the implementation of innovative strategies to address this high risk of being LTFU, reducing either the cost or the distance to the health facility.

Suggested Citation

  • Roger T. Buju & Pierre Z. Akilimali & Erick N. Kamangu & Gauthier K. Mesia & Jean Marie N. Kayembe & Hippolyte N. Situakibanza, 2022. "Incidence and Predictors of Loss to Follow Up among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study," IJERPH, MDPI, vol. 19(8), pages 1-9, April.
  • Handle: RePEc:gam:jijerp:v:19:y:2022:i:8:p:4631-:d:791894
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/8/4631/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/19/8/4631/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Roger T. Buju & Pierre Z. Akilimali & Erick N. Kamangu & Gauthier K. Mesia & Jean Marie N. Kayembe & Hippolyte N. Situakibanza, 2022. "Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study," IJERPH, MDPI, vol. 19(3), pages 1-13, January.
    2. Pierre Zalagile Akilimali & Patou Masika Musumari & Espérance Kashala-Abotnes & Patrick Kalambayi Kayembe & François B Lepira & Paulin Beya Mutombo & Thorkild Tylleskar & Mapatano Mala Ali, 2017. "Disclosure of HIV status and its impact on the loss in the follow-up of HIV-infected patients on potent anti-retroviral therapy programs in a (post-) conflict setting: A retrospective cohort study fro," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-13, February.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Roger T. Buju & Pierre Z. Akilimali & Nguyen-Toan Tran & Erick N. Kamangu & Gauthier K. Mesia & Jean Marie N. Kayembe & Hippolyte N. Situakibanza, 2022. "Determinants of Survival of HIV Patients Receiving Dolutegravir: A Prospective Cohort Study in Conflict-Affected Bunia, Democratic Republic of Congo," IJERPH, MDPI, vol. 19(16), pages 1-10, August.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Roger T. Buju & Pierre Z. Akilimali & Erick N. Kamangu & Gauthier K. Mesia & Jean Marie N. Kayembe & Hippolyte N. Situakibanza, 2022. "Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study," IJERPH, MDPI, vol. 19(3), pages 1-13, January.
    2. Roger T. Buju & Pierre Z. Akilimali & Nguyen-Toan Tran & Erick N. Kamangu & Gauthier K. Mesia & Jean Marie N. Kayembe & Hippolyte N. Situakibanza, 2022. "Determinants of Survival of HIV Patients Receiving Dolutegravir: A Prospective Cohort Study in Conflict-Affected Bunia, Democratic Republic of Congo," IJERPH, MDPI, vol. 19(16), pages 1-10, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:8:p:4631-:d:791894. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.